Understanding the Shift from PCOS to PMOS
The rebranding of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovary Syndrome (PMOS) marks a pivotal moment in women’s health. As of spring 2026, 56 medical societies and patient organizations have concluded that PCOS is not solely a condition related to the ovaries but a multifaceted metabolic disorder. This change is crucial, particularly because around 170 million women worldwide are affected, yet an alarming 70% of cases go undetected.
The Metabolic Focus of Diagnosis
The new definition highlights the metabolic aspects of this condition. Approximately 85% of women with PMOS suffer from insulin resistance, increasing their risk of developing diabetes by fourfold. Clinical indicators often include irregular menstrual cycles, abnormal blood sugar levels, excessive hair growth, severe acne, and sleep apnea.
Medical professionals are increasingly adopting interdisciplinary approaches in diagnostics. Essential processes now involve not only ultrasound examinations of the ovaries but also comprehensive blood tests to assess hormone levels, such as testosterone, LH, FSH, and insulin.
Advancements in Medication: The Arrival of Semaglutide
As we move closer to late summer 2026, significant advancements in treatment are set to occur. On May 22, 2026, the European Medicines Agency (EMA) issued a positive recommendation for an oral Semaglutide tablet, with market approval anticipated by mid-August. This is a welcome development for many women, as studies indicate that 46.5% prefer tablet forms of medication over injections.
Nevertheless, Semaglutide is only one piece of a larger puzzle. Research involving GLP-1 receptor agonists and SGLT2 inhibitors suggests further protective effects. Preliminary data from spring 2026 indicate that SGLT2 inhibitors can reduce Alzheimer’s risk by 43%, while GLP-1 treatments may lower the risk by 33%. Continuous glucose monitoring (CGM) also correlates with a significant drop in coronary heart disease risks.
Muscle Loss Concerns: Experts Sound the Alarm
While studies reveal substantial success in weight reduction—between 17% and 21% with Tirzepatide and Semaglutide—nutrition experts are raising red flags. The German Society for Nutritional Medicine (DGEM) warned in July 2026 about the risk of significant muscle mass loss, which poses a threat to long-term metabolic health.
To combat this muscle loss, experts recommend a structured accompanying therapy that includes:
– Targeted strength and endurance training to maintain muscle mass.
– Increased protein intake (1.2 to 1.6 grams per kilogram of body weight).
– Close dietary consultations to avoid nutrient deficiencies.
A Zurich study involving adolescents further showcases the complex nature of treatment. Although some participants experienced significant weight loss with Liraglutide, over half discontinued treatment due to gastrointestinal side effects.
Holistic Approaches and Digital Support
In parallel to pharmacological advancements, holistic approaches are gaining traction. Nutrients such as inositol, vitamin D, magnesium, and zinc are being combined with physiotherapy techniques like osteopathy, aiming to naturally support hormonal balance and insulin sensitivity.
Moreover, digital platforms are emerging to assist those affected; the “PCOS Harmony” project won recognition at the Startup Weekend in Mittelhessen in late May 2026. Such communities aim to shorten the often lengthy search for appropriate treatments.
Research: A New Approach Beyond Weight Focus
The upcoming Semaglutide tablet represents a significant leap forward—but without means to support muscle retention, muscle loss remains a concern. Strategies that involve targeted strength training and heightened protein intake are essential for safeguarding metabolic health in the long term.
Interestingly, research is also shifting toward weight-neutral alternatives. The EASE study, commencing in August 2026 at the University of Giessen, will explore general well-being and mindfulness with a focus on reducing stigma.
In the long run, groundbreaking peptides could redefine treatment landscapes. Researchers recently identified a natural protein (BRP) that has induced satiety signals in animal studies without nausea. However, experts estimate that it may take five to ten years before such treatments are applicable to humans.
Disclaimer: This article does not constitute financial advice or purchase/sale recommendations. Market and company data is subject to change; investing can lead to significant losses. Our contributions are created or reviewed with AI assistance and may be partially or fully automated.
